Xtandi - 40 mg soft capsules, PF-06821497, PF-06821497, Tablet to match placebo for pf-06821497 125mg, Tablet to match placebo for pf-06821497 250mg
C2321008
Phase 3 small_molecule active
Quick answer
Xtandi - 40 mg soft capsules, PF-06821497, PF-06821497, Tablet to match placebo for pf-06821497 125mg, Tablet to match placebo for pf-06821497 250mg for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active